Corcept director sells 26,685 shares after exercise

Rhea-AI Filing Summary

For CORCEPT THERAPEUTICS INC (CORT), director Kimberly Park reported an option exercise and related share dispositions on August 26, 2026. She exercised 30,000 stock options to acquire 30,000 shares of common stock at an exercise price of $13.49 per share, from a grant that is described as fully exercisable and expires on September 17, 2029. To fund the exercise, 3,315 shares of common stock were withheld by the issuer as payment of the exercise price, and 26,685 shares of common stock were sold at a weighted average price of $122.5471 per share, with actual sale prices ranging from $122.50 to $122.80. After this transaction, 30,000 stock options remain reported as directly owned.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Park Kimberly

Role Director

Sold 26,685 shs ($3.27M)

Approx. gross sale proceeds $3.27M

Approx. exercise cost $405K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F3	30,000	$0.00	$0.00
Exercise	Common Stock	30,000	$13.49	$405K
Exercise Price Payment	Common Stock F1	3,315	$122.09	$405K
Sale	Common Stock F2	26,685	$122.5471	$3.27M

Holdings After Transaction: Stock Option (right to buy) — 30,000 shares (Direct); Common Stock — 0 shares (Direct)

Footnotes (3)

1. F1. These shares were withheld by the Issuer in order to cover the exercise price in connection with the net exercise of stock options reported herein.
2. F2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $122.50 to $122.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
3. F3. Fully exercisable.

Key Figures

Options Exercised: 30,000 stock options Exercise Price: $13.49 per share Shares Acquired: 30,000 shares of common stock +5 more

8 metrics

Options Exercised 30,000 stock options Exercised on August 26, 2026 to acquire common stock

Exercise Price $13.49 per share Exercise price for 30,000 stock options into common stock

Shares Acquired 30,000 shares of common stock Received upon option exercise on August 26, 2026

Shares Withheld for Exercise Price 3,315 shares Delivered/withheld to pay the option exercise price at $122.09 per share

Shares Sold 26,685 shares Common stock sold on August 26, 2026

Weighted Average Sale Price $122.5471 per share Weighted average for 26,685 shares sold; range $122.50–$122.80

Option Expiration Date September 17, 2029 Expiration date of the stock option grant exercised in part

Options Remaining 30,000 stock options Directly owned stock options reported following the transactions

Key Terms

Stock Option (right to buy, Exercise or conversion of derivative security, net exercise of stock options, weighted average sale price, +1 more

5 terms

Stock Option (right to buy financial

"security_title": "Stock Option (right to buy)"

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security"

net exercise of stock options financial

"in order to cover the exercise price in connection with the net exercise of stock options"

weighted average sale price financial

"Represents the weighted average sale price for the entire number of shares sold"

Payment of exercise price by delivering or withholding securities financial

"transaction_code_description": "Payment of exercise price by delivering or withholding securities"

FAQ

What did CORT director Kimberly Park report on this Form 4?

Kimberly Park reported exercising 30,000 stock options of Corcept Therapeutics (CORT) at an exercise price of $13.49 per share, acquiring 30,000 common shares, then having some shares withheld to pay the exercise price and selling additional shares on August 26, 2026.

How many CORT stock options did Kimberly Park exercise and at what price?

She exercised 30,000 stock options for Corcept Therapeutics (CORT) at an exercise price of $13.49 per share, receiving 30,000 shares of common stock in the transaction reported for August 26, 2026.

How many CORT shares did Kimberly Park sell and at what price range?

She sold 26,685 shares of Corcept Therapeutics (CORT) common stock at a weighted average price of $122.5471 per share, with individual sale prices ranging from $122.50 to $122.80 per share, on August 26, 2026.

How many CORT shares were withheld to pay the option exercise price?

In connection with the option exercise, 3,315 shares of Corcept Therapeutics (CORT) common stock were withheld by the issuer to cover the exercise price for the net exercise of the stock options reported.

Does Kimberly Park still hold Corcept Therapeutics stock options after this transaction?

Yes. After the reported transactions, 30,000 stock options on Corcept Therapeutics (CORT) common stock remain reported as directly owned, and this option grant is described as fully exercisable with an expiration date of September 17, 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:30 PM Accepted by SEC EDGAR 08/28/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Park Kimberly

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/26/2026		M		30,000	A	$13.49	30,000	D
Common Stock	08/26/2026		F(1)		3,315	D	$122.09	26,685	D
Common Stock	08/26/2026		S		26,685	D	$122.5471(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.49	08/26/2026		M			30,000	(3)	09/17/2029	Common Stock	30,000	$0.00	30,000	D

Explanation of Responses:

1. These shares were withheld by the Issuer in order to cover the exercise price in connection with the net exercise of stock options reported herein.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $122.50 to $122.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

3. Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Kimberly Park	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)